MIR503

Summary

MIR503 (microRNA 503, HGNC:32138) is a microRNA gene on chromosome Xq26.3.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 574506 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32138
Approved symbol	MIR503
Name	microRNA 503
Location	Xq26.3
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-503
Ensembl gene	ENSG00000208005
Ensembl biotype	miRNA
OMIM	300865
Entrez	574506
RNAcentral	URS00006588D4 — miRNA, 71 nt, 2 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000385270

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000385270 — 1 exons

Exon	Start	End
ENSE00001500276	134546328	134546398

Expression profiles

Bgee: expression breadth broad, 64 present calls, max score 91.48.

Top tissues by expression

64 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
placenta	UBERON:0001987	91.48	gold quality
adrenal tissue	UBERON:0018303	83.06	gold quality
endometrium	UBERON:0001295	75.71	gold quality
muscle of leg	UBERON:0001383	74.47	gold quality
adult mammalian kidney	UBERON:0000082	74.35	gold quality
blood	UBERON:0000178	74.31	gold quality
left ovary	UBERON:0002119	74.14	gold quality
gastrocnemius	UBERON:0001388	73.70	gold quality
right adrenal gland	UBERON:0001233	73.13	gold quality
ovary	UBERON:0000992	72.93	gold quality
heart	UBERON:0000948	72.83	gold quality
tibial artery	UBERON:0007610	71.50	gold quality
heart left ventricle	UBERON:0002084	71.39	gold quality
kidney	UBERON:0002113	71.33	gold quality
right atrium auricular region	UBERON:0006631	70.91	gold quality
body of stomach	UBERON:0001161	70.34	gold quality
left coronary artery	UBERON:0001626	69.91	gold quality
left uterine tube	UBERON:0001303	69.61	gold quality
left adrenal gland	UBERON:0001234	68.68	gold quality
stomach	UBERON:0000945	68.19	gold quality
lower esophagus muscularis layer	UBERON:0035833	67.94	gold quality
left adrenal gland cortex	UBERON:0035825	67.89	gold quality
fallopian tube	UBERON:0003889	67.71	gold quality
omental fat pad	UBERON:0010414	67.55	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	67.54	gold quality
skin of abdomen	UBERON:0001416	67.13	gold quality
transverse colon	UBERON:0001157	67.11	gold quality
lung	UBERON:0002048	67.01	gold quality
myometrium	UBERON:0001296	66.98	gold quality
right lobe of liver	UBERON:0001114	66.70	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.63

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• microRNAs that can silence cyclin D1 (CCND1) include miR-503, miR-19a and miR-155, but only miR-503 suppresses the protein expression (PMID:19538740)
• Results reveal an unexpected role of Cdc25A down-regulation and the inhibitory phosphorylation of cdk2 T14 and Y15 in cell cycle quiescence during muscle differentiation and implicate miRNAs-322 and -503 in the process. (PMID:20462953)
• In diabetic muscles, miR-503 expression was remarkably higher, and it inversely correlated with cdc25 protein expression (PMID:21220732)
• MIRN503 is associated with metastatic function in hepatocellular cancer. (PMID:21495032)
• ionizing radiation could alter the expression of miR-503 and its target gene CD40 (PMID:22429276)
• failure to induce hsa-miR-503 might have a role in the accelerated growth of erythropoietic cells of thalassemic adults (PMID:22890417)
• miR-424 was downregulated in pulmonary arterial hypertension, exerted antiproliferative effects in pulmonary artery endothelial cells (PMID:23263626)
• miR-503 can simultaneously down-regulate FGF2 and VEGFA and inhibits tumor angiogenesis and growth (PMID:23352645)
• HDACs and NF-kB signaling coordinate epithelial expression of CX3CL1 to promote mucosal antimicrobial defense through suppression of the mir-424-503 gene. (PMID:23724129)
• Data suggest that endometrioid endometrial cancer tissue have decreased miR-503 levels compared to normal tissue; down-regulation of miR-503 relieves suppression of its target CCND1 (cyclin D1) which in turn accelerates cell cycle progression. (PMID:23731275)
• study revealed that miR-503 plays an important role in the pathogenesis of postmenopausal osteoporosis and contributes to a new therapeutic way for osteoporosis. (PMID:23821519)
• miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2. (PMID:23856992)
• two cell cycle-related molecules, cyclin D3 and E2F3, were identified as the direct miR-503 targets. (PMID:23967867)
• miR-503 is a tumor suppressor for glioblastoma and a favorable factor against glioma progression through targeting IGF-1R. (PMID:24378652)
• inhibits metastasis of hepatocellular carcinoma through deregulating ARHGEF19 (PMID:24405610)
• miR-503 gene is methylated in non-small cell lung cancer cells. miR-503 targets a homologous DNA region in the 3’-UTR region of the Fanconi anemia complementation group A protein (FANCA) gene and represses its expression at the transcriptional level. (PMID:24486548)
• Low MiR-503 expression is associated with non-small cell lung cancer. (PMID:24550137)
• miR-424 or miR-503 mediate anti-proliferative and anti-invasive actions of thyroid hormone receptor beta (PMID:24796297)
• Overall, our findings demonstrate a novel mechanism, mediated by elevated expression of the miR424-503 cluster, underlying TGFbeta activation and metastasis of human breast cancer. (PMID:25164015)
• Upregulation of miR-503 was the best single discriminator of malignancy. The combination of miR-34a and miR-497 underexpression discriminated carcinomas from adenomas with 100% sensitivity and 96% specificity. (PMID:25265426)
• miR-424(322)/503-dependent posttranscriptional downregulation of CDC25A cooperates with transcriptional repression of the CDC25A promoter and proteasome-mediated degradation to reduce the levels of CDC25A expression and to induce cell cycle arrest. (PMID:25266660)
• sequential expression of miR-182 and miR-503 in benign adenoma cooperatively regulates the tumour suppressor FBXW7, contributing to the malignant transformation of colon adenoma to adenocarcinoma (PMID:25269767)
• TNF-alpha or IGF1 modulate the miRNA biogenesis of some miRNAs via MAPK/ERK signalling. (PMID:25630602)
• Our results provide an extensive genome wide set of targets for miR-503, miR-103, and miR-494, and suggest that miR-503 may act as a tumor suppressor in breast cancer by its direct non-canonical targeting of DDHD2. (PMID:25653011)
• miR-503 are downregulated in Pulmonary arterial hypertension as well as apelin. Restoration of apelin and miR-424/503 levels reduces Pulmonary arterial hypertension severity. (PMID:25660363)
• miR-503 expression affects tumor cell proliferation in oesophageal cancer (PMID:25750296)
• Overexpression of miR-503 in breast cancer cell lines reduced cell proliferation through inducing G0/G1 cell cycle arrest by targeting CCND1 (PMID:26047605)
• miR-503-mediated PRMT1 could emerge as a potential important biomarker for hepatocellular carcinoma progression and metastasis (PMID:26163260)
• In patients with NSCLC, low miR-503 expression is an independent prognostic factor. (PMID:26191272)
• These findings collectively indicated an oncogene role of RNF31 in PCa progression which can be regulated by miR-503, suggesting that RNF31 could serve as a potential prognostic biomarker and therapeutic target for PCa. (PMID:26231797)
• miR503 significantly decreased the migration and invasion ability of the osteosarcoma cells, which may be mediated by the inhibition of fibroblast growth factor 2. (PMID:26461038)
• Reduced expression of miR-503 is an independent prognostic factor in cervical cancer indicating poor prognosis. (PMID:26592830)
• miR-503 inhibits cell proliferation and induces apoptosis by directly targeting E2F3 in colorectal cancer cells. (PMID:26722476)
• miR-503 acts as an ‘onco-miR’ in colorectal cancer. High miR-503 expression is associated with early recurrence and poor prognosis in colorectal cancer. (PMID:26999740)
• GATA3-driven expression of miR-503 inhibits prostate cancer progression by repressing ZNF217 expression. (PMID:27267060)
• miR-503 directly targets ZNF217 and that overexpression of miR-503 suppresses MCF-7 cell proliferation. (PMID:27539783)
• Our findings indicate that epigenetically repressed miR-503 in endometriotic stromal cells is involved in the acquisition of endometriosis-specific cellular functions. (PMID:27619772)
• Study demonstrates for the first time that PDGFR-alpha strongly inhibits endothelial and melanoma cells proliferation in a CXCL10/IP-10 dependent way, via miR-503 down-regulation. (PMID:27764787)
• Suggest a novel role of miR-503 as a regulator of vascular smooth muscle cell proliferation and migration by modulating INSR. (PMID:27829550)
• miR503 may increase sensitivity to therapies at least partially through targeting EIF4E suppression of Hepatocellular carcinoma proliferation. (PMID:27840964)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.